Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.49 ▲ +0.28
(+8.72%)
MKT CAP: $109.7M • VOL: 5.99M
52W L $3 52W H $32
LENZ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $19.1M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $18.7M | — | — |
| Gross Margin % | 97.8% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$91.1M | -$58.6M | -$72.4M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$82.1M | -$49.8M | -$70.0M |
| EBITDA (Normalized) | -$90.5M | -$58.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$69.2M | -$59.4M | -$60.4M |
| Capital Expenditures (CapEx) | $827.0K | $468.0K | — |
| Free Cash Flow (FCF) | -$70.0M | -$59.9M | -$60.4M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -27.8% | -25.2% | — |
| Cash & Short-Term Equivalents | $25.2M | $20.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $284.3M | $204.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LENZ.